相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
Elena Elimova et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz et al.
LANCET (2023)
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
Howard Safran et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
Dazhi Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding et al.
LANCET ONCOLOGY (2023)
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
John H Strickler et al.
LANCET ONCOLOGY (2023)
HER2/ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors
Marie C. Smithgall et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2023)
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial
Tadaaki Nishikawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas
Dara S. Ross et al.
MODERN PATHOLOGY (2022)
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam et al.
LANCET ONCOLOGY (2022)
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
Zefei Jiang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Ilana Schlam et al.
NPJ BREAST CANCER (2021)
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
Amanda N. Fader et al.
CLINICAL CANCER RESEARCH (2020)
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin et al.
GYNECOLOGIC ONCOLOGY (2020)
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Yumi Fujimoto et al.
SCIENTIFIC REPORTS (2020)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Angela N. Bartley et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature
Fausto Petrelli et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
M. M. Moasser
ONCOGENE (2007)
分享论文
